JohnMartinMagenauIVMD
Hematology • Ann Arbor, MIAssistant Professor, Internal Medicine, University of Michigan Medical School
Dr. Magenau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000Fax+1 734-232-7580
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2004 - 2007
Lewis Katz School of Medicine at Temple UniversityClass of 2004
Certifications & Licensure
MI State Medical License 2007 - 2026
IL State Medical License 2004 - 2008- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen Start of enrollment: 2007 Oct 01
- Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Start of enrollment: 2016 Sep 19
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsA phase 2 trial of CD24Fc for prevention of graft-versus-host disease.John Magenau, Samantha Jaglowski, Joseph Uberti, Sherif S Farag, Mary Mansour Riwes
Blood. 2024-01-04 - 4 citationsCardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score.Alexi Vasbinder, Tonimarie Catalan, Elizabeth Anderson, Catherine Chu, Megan Kotzin
Journal of the American Heart Association. 2024-01-02 - 1 citationsComparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.David G Frame, Marcus Geer, Salena Kasha, Denise Markstrom, Gianni Scappaticci
Frontiers in Immunology. 2024-01-01
Abstracts/Posters
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...John M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot StudyJohn M. Magenau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
If I’m Immunocompromised, Should I Keep Wearing My Mask Once I’m Vaccinated?May 28th, 2021
OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRJanuary 27th, 2020
A Phase II Trial of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell TransplantJanuary 21st, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
